Literature DB >> 21541975

Disparities at presentation, diagnosis, treatment, and survival in African American men, affected by prostate cancer.

Ganna Chornokur1, Kyle Dalton, Meghan E Borysova, Nagi B Kumar.   

Abstract

BACKGROUND: Prostate cancer (PCa) remains the most common malignancy and the second leading cause of cancer death among men in the United States. PCa exhibits the most striking racial disparity, as African American men are at 1.4 times higher risk of being diagnosed, and 2-3 times higher risk of dying of PCa, compared to Caucasian men. The etiology of the disparity has not been clearly elucidated. The objective of this article is to critically review the literature and summarize the most prominent PCa racial disparities accompanied by proposed explanations.
METHODS: The present literature on disparities at presentation, diagnosis, treatment, and survival of African American men affected by PCa was systematically reviewed. Original research as well as relevant review articles were included.
RESULTS: African American men persistently present with more advanced disease than Caucasian men, are administered different treatment regimens than Caucasian men, and have shorter progression-free survival following treatment. In addition, African American men report more treatment-related side-effects that translates to the diminished quality of life (QOL).
CONCLUSIONS: PCa racial disparity exists at stages of presentation, diagnosis, treatment regimens, and subsequent survival, and the QOL. The disparities are complex involving biological, socio-economic, and socio-cultural determinants. These mounting results highlight an urgent need for future clinical, scientific, and socio-cultural research involving transdisciplinary teams to elucidate the causes for PCa racial disparities.
Copyright © 2010 Wiley-Liss, Inc.

Entities:  

Mesh:

Year:  2010        PMID: 21541975      PMCID: PMC3083484          DOI: 10.1002/pros.21314

Source DB:  PubMed          Journal:  Prostate        ISSN: 0270-4137            Impact factor:   4.104


  82 in total

1.  Race/ethnicity and the receipt of watchful waiting for the initial management of prostate cancer.

Authors:  Vickie L Shavers; Martin L Brown; Arnold L Potosky; Carrie N Klabunde; W W Davis; Judd W Moul; Angela Fahey
Journal:  J Gen Intern Med       Date:  2004-02       Impact factor: 5.128

2.  Admixture mapping identifies 8q24 as a prostate cancer risk locus in African-American men.

Authors:  Matthew L Freedman; Christopher A Haiman; Nick Patterson; Gavin J McDonald; Arti Tandon; Alicja Waliszewska; Kathryn Penney; Robert G Steen; Kristin Ardlie; Esther M John; Ingrid Oakley-Girvan; Alice S Whittemore; Kathleen A Cooney; Sue A Ingles; David Altshuler; Brian E Henderson; David Reich
Journal:  Proc Natl Acad Sci U S A       Date:  2006-08-31       Impact factor: 11.205

3.  Racial differences in treatment of early-stage prostate cancer.

Authors:  Kathryn E Richert-Boe; Sheila Weinmann; Jean A Shapiro; Benjamin A Rybicki; Shelley M Enger; Stephen K Van Den Eeden; Noel S Weiss
Journal:  Urology       Date:  2008-02-15       Impact factor: 2.649

4.  Serum insulin-like growth factor-I levels and prostate cancer risk--interpreting the evidence.

Authors:  P Cohen
Journal:  J Natl Cancer Inst       Date:  1998-06-17       Impact factor: 13.506

5.  Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer.

Authors:  Steven B Zeliadt; Scott D Ramsey; David F Penson; Ingrid J Hall; Donatus U Ekwueme; Leonard Stroud; Judith W Lee
Journal:  Cancer       Date:  2006-05-01       Impact factor: 6.860

6.  Radical prostatectomy: lower rates among African-American men.

Authors:  P J Imperato; R P Nenner; T O Will
Journal:  J Natl Med Assoc       Date:  1996-09       Impact factor: 1.798

7.  Patterns in prostate-specific antigen test use and digital rectal examinations in the Behavioral Risk Factor Surveillance System, 2002-2006.

Authors:  Louie E Ross; Yhenneko J Taylor; Lisa C Richardson; Daniel L Howard
Journal:  J Natl Med Assoc       Date:  2009-04       Impact factor: 1.798

8.  The androgen receptor CAG and GGN repeat polymorphisms and prostate cancer susceptibility in African-American men: results from the Flint Men's Health Study.

Authors:  Ethan M Lange; Aruna V Sarma; Anna Ray; Yunfei Wang; Lindsey A Ho; Sarah A Anderson; Julie M Cunningham; Kathleen A Cooney
Journal:  J Hum Genet       Date:  2008-01-24       Impact factor: 3.172

9.  IGF-1 and IGFBP-3: Risk of prostate cancer among men in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.

Authors:  Jocelyn M Weiss; Wen-Yi Huang; Sabina Rinaldi; Thomas R Fears; Nilanjan Chatterjee; David Chia; E David Crawford; Rudolf Kaaks; Richard B Hayes
Journal:  Int J Cancer       Date:  2007-11-15       Impact factor: 7.396

10.  Circulating levels of leptin, adiposity and breast cancer risk.

Authors:  M-H Wu; Y-C Chou; W-Y Chou; G-C Hsu; C-H Chu; C-P Yu; J-C Yu; C-A Sun
Journal:  Br J Cancer       Date:  2009-02-24       Impact factor: 7.640

View more
  143 in total

1.  Cancer incidence in Nigeria: a report from population-based cancer registries.

Authors:  Elima Jedy-Agba; Maria Paula Curado; Olufemi Ogunbiyi; Emmanuel Oga; Toyin Fabowale; Festus Igbinoba; Gloria Osubor; Theresa Otu; Henry Kumai; Alice Koechlin; Patience Osinubi; Patrick Dakum; William Blattner; Clement A Adebamowo
Journal:  Cancer Epidemiol       Date:  2012-05-22       Impact factor: 2.984

2.  Treatment of men with high-risk prostate cancer based on race, insurance coverage, and access to advanced technology.

Authors:  Robert Steven Gerhard; Dattatraya Patil; Yuan Liu; Kenneth Ogan; Mehrdad Alemozaffar; Ashesh B Jani; Omer N Kucuk; Viraj A Master; Theresa W Gillespie; Christopher P Filson
Journal:  Urol Oncol       Date:  2017-01-12       Impact factor: 3.498

3.  Overall Survival of Black and White Men With Metastatic Castration-Resistant Prostate Cancer Treated With Docetaxel.

Authors:  Susan Halabi; Sandipan Dutta; Catherine M Tangen; Mark Rosenthal; Daniel P Petrylak; Ian M Thompson; Kim N Chi; John C Araujo; Christopher Logothetis; David I Quinn; Karim Fizazi; Michael J Morris; Mario A Eisenberger; Daniel J George; Johann S De Bono; Celestia S Higano; Ian F Tannock; Eric J Small; William Kevin Kelly
Journal:  J Clin Oncol       Date:  2018-12-21       Impact factor: 44.544

Review 4.  Prostate Cancer Screening.

Authors:  William J Catalona
Journal:  Med Clin North Am       Date:  2018-03       Impact factor: 5.456

5.  DNA methylation profiles in African American prostate cancer patients in relation to disease progression.

Authors:  Rohina Rubicz; Shanshan Zhao; Milan Geybels; Jonathan L Wright; Suzanne Kolb; Brandy Klotzle; Marina Bibikova; Dean Troyer; Raymond Lance; Elaine A Ostrander; Ziding Feng; Jian-Bing Fan; Janet L Stanford
Journal:  Genomics       Date:  2016-02-21       Impact factor: 5.736

6.  A multidimensional view of racial differences in access to prostate cancer care.

Authors:  Craig Evan Pollack; Katrina A Armstrong; Nandita Mitra; Xinwei Chen; Katelyn R Ward; Archana Radhakrishnan; Michelle S Wong; Justin E Bekelman; Charles C Branas; Karin V Rhodes; David T Grande
Journal:  Cancer       Date:  2017-07-20       Impact factor: 6.860

7.  Estrogen receptor alpha gene polymorphisms and risk of prostate cancer: a meta-analysis involving 18 studies.

Authors:  Zhenwei Gu; Gang Wang; Weiguo Chen
Journal:  Tumour Biol       Date:  2014-03-01

8.  Racial/Ethnic Disparity in Treatment for Prostate Cancer: Does Cancer Severity Matter?

Authors:  Kelvin A Moses; Heather Orom; Alicia Brasel; Jacquelyne Gaddy; Willie Underwood
Journal:  Urology       Date:  2016-09-22       Impact factor: 2.649

9.  Hyperglycemia and prostate cancer recurrence in men treated for localized prostate cancer.

Authors:  J L Wright; S R Plymate; M P Porter; J L Gore; D W Lin; E Hu; S B Zeliadt
Journal:  Prostate Cancer Prostatic Dis       Date:  2013-03-05       Impact factor: 5.554

10.  Relationship of early-onset baldness to prostate cancer in African-American men.

Authors:  Charnita Zeigler-Johnson; Knashawn H Morales; Elaine Spangler; Bao-Li Chang; Timothy R Rebbeck
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-26       Impact factor: 4.254

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.